Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-12
DOI
10.3389/fphar.2020.00656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A nicotinamide phosphoribosyltransferase–GAPDH interaction sustains the stress-induced NMN/NAD+ salvage pathway in the nucleus
- (2020) Ambra A Grolla et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis
- (2020) Giorgia Colombo et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells
- (2019) Cristina Travelli et al. CANCER RESEARCH
- ADP-ribosylation and intracellular traffic: an emerging role for PARP enzymes
- (2019) Giovanna Grimaldi et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle dependent in mammalian cells and its inhibition slows cell growth
- (2019) Petr Svoboda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling
- (2019) Sudhir Chowdhry et al. NATURE
- Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
- (2019) Yi Zhu et al. PHARMACOLOGY & THERAPEUTICS
- NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
- (2019) Antonio Lucena-Cacace et al. Frontiers in Oncology
- Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer
- (2019) Kuojun Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice
- (2019) Mitsukuni Yoshida et al. Cell Metabolism
- Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
- (2019) Ekaterina Pylaeva et al. Jove-Journal of Visualized Experiments
- NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer
- (2019) Valentina Audrito et al. Frontiers in Immunology
- Updates on the epigenetic roles of sirtuins
- (2019) Tatsiana Kosciuk et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis
- (2019) Eloi Franco-Trepat et al. Journal of Clinical Medicine
- Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group
- (2019) Cristina Travelli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
- (2019) Nathan R. Fons et al. Nature Communications
- Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation
- (2019) Antonella Managò et al. Nature Communications
- Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis
- (2019) Chengjian Ji et al. Annals of Translational Medicine
- Fragment-based discovery of a potent NAMPT inhibitor
- (2018) Alla Korepanova et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen
- (2018) Daniel S. Palacios et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges
- (2018) Maria Dalamaga et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- NAMPT: a pleiotropic modulator of monocytes and macrophages
- (2018) Cristina Travelli et al. PHARMACOLOGICAL RESEARCH
- Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation
- (2018) Dominik Kraus et al. CELLULAR ONCOLOGY
- Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
- (2018) Valentina Audrito et al. Oncotarget
- Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment
- (2018) Yoko Ogino et al. Oncotarget
- Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates
- (2018) Christopher S Neumann et al. MOLECULAR CANCER THERAPEUTICS
- FK866 inhibits the epithelial‑mesenchymal transition of hepatocarcinoma MHCC97‑H cells
- (2018) Bin Zhang et al. Oncology Letters
- Loss of the Chr16p11.2 ASD candidate gene QPRT leads to aberrant neuronal differentiation in the SH-SY5Y neuronal cell model
- (2018) Denise Haslinger et al. Molecular Autism
- NAD metabolism fuels human and mouse intestinal inflammation
- (2017) Romana R Gerner et al. GUT
- Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
- (2017) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity
- (2017) Cristina Travelli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway
- (2017) Ling-Fang Wang et al. Lipids in Health and Disease
- Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
- (2017) Genshi Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
- (2017) Julie L. Wilsbacher et al. MOLECULAR CANCER THERAPEUTICS
- NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation
- (2017) Chen-Xiang Chen et al. NEUROSCIENCE
- From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish
- (2017) Steven Cassar et al. TOXICOLOGICAL SCIENCES
- Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery
- (2017) Wei Chen et al. ACS Medicinal Chemistry Letters
- A phase 1 trial of GMX1777: An inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)
- (2017) M. J. Pishvaian et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells
- (2017) David Estoppey et al. Scientific Reports
- Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase
- (2016) Wei Chen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Intracellular NAD+ levels are associated with LPS-induced TNF- release in pro-inflammatory macrophages
- (2016) A. J. Al-Shabany et al. BIOSCIENCE REPORTS
- Extracellular nicotinamide phosphoribosyltransferase, a new cancermetabokine
- (2016) Ambra A Grolla et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines
- (2016) D. L. Misner et al. Cardiovascular Toxicology
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
- (2016) Jinhong Bai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors
- (2016) Mark Zak et al. JOURNAL OF MEDICINAL CHEMISTRY
- NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177 Lu-DOTATATE Treatment of Neuroendocrine Tumors
- (2016) Anna-Karin Elf et al. JOURNAL OF NUCLEAR MEDICINE
- Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
- (2016) O. Abu Aboud et al. MOLECULAR CANCER THERAPEUTICS
- A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
- (2016) Marine Barraud et al. Oncotarget
- Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway
- (2016) Jun Feng et al. Biomed Research International
- Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma
- (2016) Simone M. Goldinger et al. JAMA Dermatology
- Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility
- (2015) Mark Zak et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells
- (2015) A. Cagnetta et al. CLINICAL CANCER RESEARCH
- Physiological and pathophysiological roles of NAMPT and NAD metabolism
- (2015) Antje Garten et al. Nature Reviews Endocrinology
- Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer
- (2015) Deepak Sampath et al. PHARMACOLOGY & THERAPEUTICS
- Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma
- (2015) Ambra A. Grolla et al. Pigment Cell & Melanoma Research
- Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid
- (2015) Jacqueline M. Tarrant et al. TOXICOLOGY MECHANISMS AND METHODS
- Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement
- (2015) S. Theeramunkong et al. MedChemComm
- NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
- (2015) Z Moore et al. Cell Death & Disease
- Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors
- (2015) Sara Duarte-Pereira et al. Oncotarget
- Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model
- (2015) Giovanna Sociali et al. Oncotarget
- Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT
- (2015) Xia Wang et al. Scientific Reports
- Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase
- (2015) Tian-Ying Xu et al. Scientific Reports
- Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid
- (2015) Jacqueline M. Tarrant et al. TOXICOLOGY MECHANISMS AND METHODS
- Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders
- (2015) Fabrizio Montecucco et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NFκB Signaling and Inflammatory Lung Injury
- (2015) Sara M. Camp et al. Scientific Reports
- Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia
- (2014) Valentina Audrito et al. BLOOD
- Synergy between the NAMPT Inhibitor GMX1777(8) and Pemetrexed in Non-Small Cell Lung Cancer Cells Is Mediated by PARP Activation and Enhanced NAD Consumption
- (2014) M. Chan et al. CANCER RESEARCH
- Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase
- (2014) Angela Oh et al. CHEMBIOCHEM
- Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity
- (2014) Debora Soncini et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- NAD+ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study
- (2014) Shuraila F. Zerp et al. RADIOTHERAPY AND ONCOLOGY
- Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase
- (2014) Tanja S. Zabka et al. TOXICOLOGICAL SCIENCES
- Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity
- (2013) A. Cagnetta et al. BLOOD
- The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
- (2013) F. Sahm et al. CANCER RESEARCH
- Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
- (2013) By Fabrizio Montecucco et al. CURRENT DRUG TARGETS
- Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions
- (2013) Zhongjie Sun et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
- (2013) Ubaldina Galli et al. JOURNAL OF MEDICINAL CHEMISTRY
- The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody
- (2013) Aimable Nahimana et al. LEUKEMIA & LYMPHOMA
- Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
- (2012) Ilirjana Bajrami et al. EMBO Molecular Medicine
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells
- (2011) C. Travelli et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil
- (2011) Xiang-Ming Che ONCOLOGY REPORTS
- Nicotinamide Phosphoribosyltransferase/Visfatin Does Not Catalyze Nicotinamide Mononucleotide Formation in Blood Plasma
- (2011) Nobumasa Hara et al. PLoS One
- Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
- (2011) Michele Cea et al. PLoS One
- Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells
- (2010) Gabriele Zoppoli et al. EXPERIMENTAL HEMATOLOGY
- A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor
- (2010) U. H. Olesen et al. MOLECULAR CANCER THERAPEUTICS
- QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study
- (2009) Nora Hinsch et al. BMC CANCER
- Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
- (2009) Anne von Heideman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Nicotinamide Phosphoribosyltransferase: A Molecular Link between Metabolism, Inflammation, and Cancer
- (2009) M. Galli et al. CANCER RESEARCH
- A Novel Potent Nicotinamide Phosphoribosyltransferase Inhibitor Synthesized via Click Chemistry
- (2009) Giampiero Colombano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner
- (2009) Frédéric Van Gool et al. NATURE MEDICINE
- Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE
- (2009) Santina Bruzzone et al. PLoS One
- Anticancer agent CHS-828 inhibits cellular synthesis of NAD
- (2008) Uffe Høgh Olesen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More